SRPT

Sarepta Therapeutics,, Inc. Common Stock

17.82

USD

+0.25

+1.42%

Nov 06, 15:59 UTC -5

Closed

After-Market

17.82

0.00

+0.03%

Sarepta Therapeutics,, Inc. Common Stock (SRPT) Earnings

SRPT Earnings Reports

Positive Surprise Ratio

SRPT beat 20 of 44 last estimates.

45%

Next Report

Date of Next Report

Feb 23, 2027

Estimate for Q4 26 (Revenue/ EPS)

$358.67M

-$0.06

Implied change from Q3 26 (Revenue/ EPS)

-5.95%

-146.15%

Implied change from Q4 25 (Revenue/ EPS)

-19.02%

-98.47%

Sarepta Therapeutics,, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, SRPT reported earnings of 0.13 USD per share (EPS) for Q3 26, beating the estimate of 0.06 USD, resulting in a 99.39% surprise. Revenue reached 381.35 million, compared to an expected 360.02 million, with a 5.92% difference. The market reacted with a +1.42% price change (close before vs. close after earnings).

Looking ahead to Q4 26, 14 analysts forecast an EPS of -0.06 USD, with revenue projected to reach 358.67 million USD, implying an decrease of -146.15% EPS, and decrease of -5.95% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Novavax Inc

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.34

Actual

-$0.19

Surprise

+44.56%

Eton Pharmaceutcials, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.31

Actual

$1.06

Surprise

+232.50%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Monte Rosa Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.29

Actual

$0.03

Surprise

+110.09%

PUMA BIOTECHNOLOGY INC

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.15

Surprise

+63.40%

Allogene Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.15

Actual

-$0.15

Surprise

+0.33%

Arcturus Therapeutics Holdings Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.69

Actual

-$0.26

Surprise

+62.44%

Anika Therapeutics Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

$0.06

Actual

$0.28

Surprise

+373.86%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Vera Therapeutics, Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.65

Actual

-$1.30

Surprise

+21.33%

FAQ

What were Sarepta Therapeutics,, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Sarepta Therapeutics,, Inc. Common Stock reported EPS of $0.13, beating estimates by 99.39%, and revenue of $381.35M, 5.92% above expectations.

How did the market react to Sarepta Therapeutics,, Inc. Common Stock's Q3 2026 earnings?

The stock price moved up 1.42%, changed from $17.57 before the earnings release to $17.82 the day after.

When is Sarepta Therapeutics,, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 23, 2027.

What are the forecasts for Sarepta Therapeutics,, Inc. Common Stock's next earnings report?

Based on 14 analysts, Sarepta Therapeutics,, Inc. Common Stock is expected to report EPS of -$0.06 and revenue of $358.67M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.